Skip to main content
MRNA
NASDAQ Life Sciences

Moderna Swings to $162M Q3 Profit, Raises 2026 Revenue Growth Outlook to 15%-25%

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$252.01
Mkt Cap
$96.399B
52W Low
$22.28
52W High
$261
52W Position info
1031% above low
Off High info
3.4% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

MRNA has more than doubled off its 52-week low of $22.28.

Summary

Moderna posted $162 million of Q3 net income ($0.38 diluted EPS) on $1.3 billion of revenue, up 29%, and raised 2026 revenue growth guidance to 15%-25% while lifting its year-end cash outlook to $8.1-$8.3 billion.


Key Events · Earnings and Guidance · MRNA

  • Q3 Swing to Profitability

    Net income was $162 million, or $0.38 per diluted share, versus a $(200) million net loss and $(0.51) per share in Q3 2025, a $362 million year-over-year improvement.

  • Revenue Up 29% to $1.3 Billion

    Total revenue rose to $1.3 billion from $1.0 billion, with $780 million in the U.S. and $533 million international, driven by higher COVID vaccine sales under government partnerships.

  • 2026 Guidance Raised

    Full-year revenue growth outlook lifted to 15%-25% from up to 10%; R&D trimmed to about $2.7 billion from about $2.9 billion, roughly $0.2 billion of operating expense improvement.

  • Year-End Cash Outlook Jumps

    Cash and investments are now expected at $8.1-$8.3 billion versus the prior $4.7-$5.2 billion outlook, reflecting the $2.6 billion net convertible note proceeds and better operations; Q3 cash stood at $8.0 billion.


Analysis · MRNA · Life Sciences

A year after posting a $(200) million loss, Moderna delivered $162 million of net income on $1.3 billion of revenue, up 29%, and lifted full-year revenue growth guidance to 15%-25% from up to 10%. The R&D budget was trimmed to about $2.7 billion, and the company now expects to end 2026 with $8.1-$8.3 billion of cash, up sharply from the prior $4.7-$5.2 billion outlook, helped by the $2.6 billion net raised from convertible notes. For a company that was burning cash and carrying a going-concern-adjacent narrative a year ago, the combination of profitability, a higher revenue trajectory and a much larger cash cushion changes the near-term funding picture. The GSK settlement on October 28 removes a litigation overhang with no payment required.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MRNA was trading at $252.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $96.4B. The 52-week trading range was $22.28 to $261.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MRNA - Latest Insights

MRNA
Nov 12, 2026, 7:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $247.31
Real-time Price: $199.30 info
Change: -$48.01 (-19%) info
Market Cap: $78.901B info
MRNA
Nov 07, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $256.92
Real-time Price: $199.30 info
Change: -$57.62 (-22%) info
Market Cap: $78.901B info
MRNA
Nov 06, 2026, 4:06 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $255.50
Real-time Price: $199.30 info
Change: -$56.20 (-22%) info
Market Cap: $78.901B info
MRNA
Nov 06, 2026, 1:11 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $258.37
Real-time Price: $199.30 info
Change: -$59.07 (-23%) info
Market Cap: $78.901B info
MRNA
Nov 06, 2026, 7:07 AM EST
Source: Seeking Alpha
Importance Score:
9
Price at Filing: $265.00
Real-time Price: $199.30 info
Change: -$65.70 (-25%) info
Market Cap: $78.901B info